Wave Life Sciences reported total assets of $507.9 million as of September 30, 2026, a decrease from $638.5 million at year-end 2025, primarily driven by a reduction in cash and cash equivalents. The company transitioned a significant portion of its liquidity into marketable securities and reported 197,228,968 shares of common stock outstanding as of October 21, 2026.
Wave Life Sciences reported Q3 2026 financial results, highlighting a cash position of $431 million and an expected runway into Q3 2028. The company is advancing its RNA editing and siRNA clinical programs, including planning for a registrational trial of WVE-006 in AATD and ongoing Phase 2a dosing for WVE-007 in obesity.
Term
Q3 2026
“Following positive FDA feedback, planning is underway for our potentially registrational trial of WVE-006 for AATD, which we believe offers an efficient path to potential full and accelerated approval, without the need for a separate confirmatory trial.”
Paul Bolno, MD, MBA, President and Chief Executive Officer
“Importantly, our PRISM platform and chemistry continue to demonstrate unique value both within our own pipeline and beyond. The advancement of a development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class siRNA with SpiNA design, with three additional collaboration programs still advancing.”
Paul Bolno, MD, MBA, President and Chief Executive Officer